Daily Dose - Apr 26th, 2024
 
 
Daily Dose | View online
 
April 26, 2024
Welcome to Editors' (re)View, a feature where the Pharma Manufacturing editors handpick notable pharma world happenings that deserve some extra consideration. See what you may have missed this week in pharma.
Beqvez, priced at $3.5 million in the U.S., is tied with CSL's hemophilia therapy as the second most expensive drug in the world.
The new 'Advanced Research Center' is part of a $1.6 billion investment initiative at the company's Darmstadt site.
Sponsored
mRNA-LNP manufacturing is fraught with obstacles, resulting in higher program risk, inflated costs, and delayed market release. With the right knowledge, companies can overcome the challenges to de-risk & optimize the path to manufacturing success.